Spyre Therapeutics (NASDAQ:SYRE) disclosed a pair of related insider transactions executed on April 1, 2026, involving its Chief Medical Officer, Sloan Sheldon. On that date, Sheldon sold 7,958 shares of common stock at $50.00 per share, producing gross proceeds of $397,900. The filing shows that the same individual concurrently exercised options to acquire 7,958 shares at an exercise price of $21.66 per share, representing a total outlay of $172,370.
After completing the sale, Sheldon directly holds zero shares of Spyre Therapeutics common stock, according to the disclosure. The exercise is linked to a broader award: a right to purchase 95,500 shares of the issuer's common stock. That award will vest in equal monthly installments over a four-year period.
The disclosed transactions were carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that was adopted on June 20, 2025. The company filing indicates both the sale and the option exercise were executed under that plan.
Market context around the timing of the sale is noteworthy. Spyre's stock traded near its 52-week high of $51.06 at the time, following a 272% gain over the prior year. Separately, InvestingPro analysis included in the filing notes the stock appears overvalued at current levels, with shares trading at $47.58 according to that platform's assessment.
Clinical program updates and analyst responses
In regulatory filings and corporate announcements around the same period, Spyre reported accelerated timelines for several clinical programs. Enrollment for SPY001, the company's antibody being evaluated in the SKYLINE platform trial for ulcerative colitis, completed ahead of schedule. The company projects Part A readouts for that study in the second quarter of 2026.
Similarly, the Phase 2 SKYWAY basket trial for rheumatoid arthritis recorded faster-than-anticipated enrollment, shifting the anticipated topline data release to the third quarter of 2026. Those shifts in timing have been cited in subsequent analyst commentary.
Leerink Partners reiterated an Outperform rating for Spyre, explicitly pointing to the expedited trial timelines as a constructive factor. Guggenheim identified Spyre as a top pick for 2026, highlighting progress in the company's rheumatoid arthritis program. Stifel raised its price target to $92 and maintained a Buy rating, referencing the potential of Spyre's TL1A monoclonal antibody, SPY002, in treating inflammatory bowel disease. BTIG also maintained a Buy rating with a $70 price target following a significant co-funding agreement between Royalty Pharma and Johnson & Johnson, which the firm said underscores the potential of Spyre's therapeutic approaches.
What the filings show and what remains in place
The combined disclosure — a sale at $50.00 per share and an option exercise at $21.66 per share on the same day — leaves the executive without direct share ownership following the transactions. The underlying option award and the 95,500-share purchase right will vest over four years in equal monthly installments, so future option exercises or sales could occur as vesting events happen. The transactions were executed under the 10b5-1 framework established June 20, 2025, which the filing identifies as the governing mechanism for these trades.
Investors and market participants tracking insider activity and trial progress will likely continue to monitor Spyre's clinical readouts and any future insider filings for further context on executive holdings and company momentum.